Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients

Journal of Nephrology

Volumn 21, Issue 3, 2008, Pages 412-420

  Locatelli, Francesco ^a   Villa, Giuseppe ^b   Messa, Piergiorgio ^c   Filippini, Armando ^d   Cannella, Giuseppe ^e   De Ferrari, Giacomo ^f   Naso, Agostino ^g   Rossi, Egidio ^h   Formica, Marco ⁱ   Lombardi, Luigi ^j   Rotolo, Ugo ^k   Conte, Ferruccio ^l  

^a A MANZONI HOSPITAL   (Italy)

^b IRCCS   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d San Giacomo Hospital   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Cliniche Universitarie Convenzionate DIMI   (Italy)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h AUSL   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j PUGLIESE CIACCIO HOSPITAL   (Italy)

^k ARNAS Civico Benfratelli G di Cristina and M Ascoli   (Italy)

^l FATEBENEFRATELLI HOSPITAL   (Italy)

more..

Author keywords

Anemia; Chronic kidney disease; Dialysis; Epoetin alfa; Erythropoiesis stimulating agent; Frequency of administration

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SIDE EFFECT; TREATMENT DURATION; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 52049113274     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Locatelli F, Aljama P, Barany P, et al; European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl 2):ii1-ii47.
2. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:439-446.
3. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-583.
4. Goodkin DA, Gimenez LF, Graber SE, Van Stone JC, Egrie JC, Okamoto DM. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: a post hoc analysis. Clin Nephrol. 1999;51:367-372.
5. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther. 2002;24:1720-1740.
6. Lui SF, Wong KC, Li PK, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Am J Nephrol. 1992;12:55-60.
7. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant. 2000;15:2014-2019.
8. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis. 2002;40:119-125.
9. Lago M, Perez-Garcia R, Garcia de Vinuesa MS, Anaya F, Valderrabano F. Efficiency of once-weekly subcutaneous administration of recombinant human erythropoietin versus three times a week administration in hemodialysis patients. Nephron. 1996;72:723-724.
10. Canaud B, Bennhold I, Delons S, et al. What is the optimum frequency of administration of r-HuEPO for correcting anemia in hemodialysis patients? Dial Transplant. 1995;24:306-309.
11. Cody J, Daly C, Campbell M, et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients. Cochrane Database Syst Rev. 2005;CD003895.
12. Barre P, Reichel H, Suranyi MG, Barth C. Efficacy of once-weekly epoetin alfa. Clin Nephrol. 2004;62:440-448.
13. Messa P, Nicolini MA, Cesana B, et al. Efficacy prospective study of different frequencies of EPO administration by i.v. and s.c. routes in renal replacement therapy patients. Nephrol Dial Transplant. 2006;21:431-436.
14. Tracey R, Greway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma: Part I: validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods. 2003;283:317-329.
15. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64:1514-1521.
16. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-1343.